HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma

Cancer Letters

Volumn 379, Issue 1, 2016, Pages 134-142

  Wang, Zhihao ^a,b   Hu, Pengchao ^b   Tang, Fang ^a   Lian, Haiwei ^c   Chen, Xiong ^b   Zhang, Yingying ^b   He, Xiaohua ^b   Liu, Wanhong ^b   Xie, Conghua ^b  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

EGFR; Glioblastoma; HDAC6; Temozolomide

Indexed keywords

A 172; CASPASE INHIBITOR; CAY 10603; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; NECROSTATIN 1; RICOLINOSTAT; TEMOZOLOMIDE; TUBASTATIN A; U 251; U 87; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; EGFR PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE;

APOPTOSIS; ARTICLE; BRAIN SURGERY; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIZATION; DRUG STRUCTURE; EGFR GENE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; HDAC6 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPHEROID CELL; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROTEIN STABILITY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84973294642     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.06.001     Document Type: Article

References (51)

1. Rich J.N., Bigner D.D. Development of novel targeted therapies in the treatment of malignant glioma. Nat. Rev. Drug Discov 2004, 3:430-446.
2. Kotliarova S., Fine H.A. SnapShot: glioblastoma multiforme. Cancer Cell 2012, 21:710. e1.
3. Ellis H.P., Greenslade M., Powell B., Spiteri I., Sottoriva A., Kurian K.M. Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front. Oncol 2015, 5:251.
4. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
5. Ecker J., Witt O., Milde T. Targeting of histone deacetylases in brain tumors. CNS Oncol 2013, 2:359-376.
6. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov 2014, 13:673-691.
7. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet 2009, 10:32-42.
8. Bruserud O., Stapnes C., Ersvaer E., Gjertsen B.T., Ryningen A. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm. Biotechnol 2007, 8:388-400.
9. Marsoni S., Damia G., Camboni G. A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 2008, 3:164-171.
10. Kaliszczak M., Trousil S., Aberg O., Perumal M., Nguyen Q.D., Aboagye E.O. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br. J. Cancer 2013, 108:342-350.
11. Seidel C., Schnekenburger M., Dicato M., Diederich M. Histone deacetylase 6 in health and disease. Epigenomics 2015, 7:103-118.
12. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
13. Kramer O.H., Mahboobi S., Sellmer A. Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol. Sci 2014, 35:501-509.
14. Zhou J., Vos C.C., Gjyrezi A., Yoshida M., Khuri F.R., Tamanoi F., et al. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J. Biol. Chem 2009, 284:9648-9655.
15. Grozinger C.M., Hassig C.A., Schreiber S.L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:4868-4873.
16. Zhang L., Liu S., Liu N., Zhang Y., Liu M., Li D., et al. Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity. Protein Cell 2015, 6:42-54.
17. Park S.J., Kim J.K., Bae H.J., Eun J.W., Shen Q., Kim H.S., et al. HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer. Cancer Lett 2014, 354:97-106.
18. Gradilone S.A., Radtke B.N., Bogert P.S., Huang B.Q., Gajdos G.B., LaRusso N.F. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res 2013, 73:2259-2270.
19. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. J. Biomed. Biotechnol 2011, 2011:875824.
20. Dhanyamraju P.K., Holz P.S., Finkernagel F., Fendrich V., Lauth M. Histone deacetylase 6 represents a novel drug target in the oncogenic Hedgehog signaling pathway. Mol. Cancer Ther 2015, 14:727-739.
21. Sun L., Hui A.M., Su Q., Vortmeyer A., Kotliarov Y., Pastorino S., et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006, 9:287-300.
22. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
23. Li L., Yang X.J. Tubulin acetylation: responsible enzymes, biological functions and human diseases. Cell. Mol. Life Sci 2015, 72:4237-4255.
24. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
25. Agnihotri S., Burrell K., Buczkowicz P., Remke M., Golbourn B., Chornenkyy Y., et al. ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents. Cancer Discov 2014, 4:1198-1213.
26. Chen Y., Meng D., Wang H., Sun R., Wang D., Wang S., et al. VAMP8 facilitates cellular proliferation and temozolomide resistance in human glioma cells. Neuro Oncol 2015, 17:407-418.
27. Munoz J.L., Rodriguez-Cruz V., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis 2014, 5:e1145.
28. Yeom S.Y., Nam D.H., Park C. RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma. Mol. Cancer Ther 2014, 13:3049-3061.
29. Prados M.D., Chang S.M., Butowski N., DeBoer R., Parvataneni R., Carliner H., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol 2009, 27:579-584.
30. Gao Y.S., Hubbert C.C., Yao T.P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J. Biol. Chem 2010, 285:11219-11226.
31. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal 2009, 2:ra84.
32. Woan K.V., Lienlaf M., Perez-Villaroel P., Lee C., Cheng F., Knox T., et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol. Oncol 2015, 9:1447-1457.
33. Wang Z., Tang F., Hu P., Wang Y., Gong J., Sun S., et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol. Rep 2016, 10.3892/or.2016.4811.
34. Wang Z., Hu P., Tang F., Xie C. HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells. Med. Oncol 2016, 33:50.
35. Li S., Liu X., Chen X., Zhang L., Wang X. Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling. Tumour Biol 2015, 36:9661-9665.
36. Nakashima H., Kaufmann J.K., Wang P.Y., Nguyen T., Speranza M.C., Kasai K., et al. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J. Clin. Invest 2015, 125:4269-4280.
37. Lienlaf M., Perez-Villarroel P., Knox T., Pabon M., Sahakian E., Powers J., et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol 2016, 10:735-750.
38. Woods D.M., Sodre A.L., Villagra A., Sarnaik A., Sotomayor E.M., Weber J. HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol. Res 2015, 3:1375-1385.
39. Serrador J.M., Cabrero J.R., Sancho D., Mittelbrunn M., Urzainqui A., Sanchez-Madrid F. HDAC6 deacetylase activity links the tubulin cytoskeleton with immune synapse organization. Immunity 2004, 20:417-428.
40. Berghoff A.S., Kiesel B., Widhalm G., Rajky O., Ricken G., Wohrer A., et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015, 17:1064-1075.
41. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys 2013, 86:343-349.
42. Huang P.H., Xu A.M., White F.M. Oncogenic EGFR signaling networks in glioma. Sci. Signal 2009, 2:re6.
43. Wheeler D.L., Dunn E.F., Harari P.M. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol 2010, 7:493-507.
44. Weihua Z., Tsan R., Huang W.C., Wu Q., Chiu C.H., Fidler I.J., et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008, 13:385-393.
45. Brand T.M., Iida M., Luthar N., Starr M.M., Huppert E.J., Wheeler D.L. Nuclear EGFR as a molecular target in cancer. Radiother. Oncol 2013, 108:370-377.
46. Ahsan A., Ramanand S.G., Whitehead C., Hiniker S.M., Rehemtulla A., Pratt W.B., et al. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 2012, 14:670-677.
47. Kanzawa T., Germano I.M., Komata T., Ito H., Kondo Y., Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11:448-457.
48. Lee J.Y., Koga H., Kawaguchi Y., Tang W., Wong E., Gao Y.S., et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J. 2010, 29:969-980.
49. Mishima Y., Santo L., Eda H., Cirstea D., Nemani N., Yee A.J., et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br. J. Haematol 2015, 169:423-434.
50. Tan X., Thapa N., Sun Y., Anderson R.A. A kinase-independent role for EGF receptor in autophagy initiation. Cell 2015, 160:145-160.
51. Guedes-Dias P., de Proenca J., Soares T.R., Leitao-Rocha A., Pinho B.R., Duchen M.R., et al. HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. Biochim. Biophys. Acta 1852, 2015:2484-2493.